Get the Stockscreener App
31.68
2.86%
0.88
After Hours:
32.78
1.10
+3.47%
Ideaya Biosciences Inc stock is traded at $31.68, with a volume of 1.02M.
It is up +2.86% in the last 24 hours and down -19.80% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
See More
Previous Close:
$30.80
Open:
$30.61
24h Volume:
1.02M
Relative Volume:
1.18
Market Cap:
$2.68B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-21.85
EPS:
-1.45
Net Cash Flow:
$-134.36M
1W Performance:
-6.08%
1M Performance:
-19.80%
6M Performance:
-27.80%
1Y Performance:
+17.42%
1-Day Range:
$30.36
$31.84
1-Week Range:
$29.70
$33.85
52-Week Range:
$23.41
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
7000 SHORELINE CT, SUITE 350, SOUTH SAN FRANCISCO, CA
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
109,325 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Renaissance Technologies LLC - MarketBeat
Scientech Research LLC Boosts Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate - MSN
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasted to Earn FY2025 Earnings of ($3.49) Per Share - MarketBeat
Deerfield Management Company L.P. Series C Sells 533,179 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Mizuho keeps stock target, outperform on Ideaya Biosciences, cites FDA update - Investing.com Canada
RBC maintains price target on Ideaya Biosciences, upbeat on daro By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) PT Lowered to $52.00 at Wedbush - MarketBeat
IDEAYA Biosciences Enters Oversold Territory (IDYA) - Nasdaq
IDEAYA Biosciences (NASDAQ:IDYA) Rating Reiterated by Royal Bank of Canada - MarketBeat
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans - Clinical Trials Arena
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans - Yahoo Finance
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stake Raised by Samlyn Capital LLC - MarketBeat
Goldman Sachs lifts Ideaya Biosciences target to $48 on study results - Investing.com Canada
Citi maintains Buy rating and $58 target on Ideaya Biosciences By Investing.com - Investing.com Canada
BTIG maintains $62 target on Ideaya Biosciences stock By Investing.com - Investing.com Canada
IDEAYA reports promising Phase 2 uveal melanoma trial data - Investing.com
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $35.00 - MarketBeat
Positive interim Phase II data for darovasertib - The Pharma Letter
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate - Benzinga
HighVista Strategies LLC Has $1.43 Million Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - The Malaysian Reserve
Ideaya Biosciences Sees Posisitive Data From Darovasertib Trial - MarketWatch
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - StockTitan
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - BioSpace
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Daro - GuruFocus.com
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 – Company Announcement - Financial Times
IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success - Seeking Alpha
Trading (IDYA) With Integrated Risk Controls - Stock Traders Daily
Ideaya Biosciences Names Pharma, Biotech Vet As GC - Law360
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 2.2% - MarketBeat
Daiwa Securities Group Inc. Has $68,000 Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel - StockTitan
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel - PR Newswire
Sofinnova Investments Inc. Grows Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Arizona State Retirement System Increases Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Victory Capital Management Inc. Buys 29,600 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Nicholas Investment Partners LP Reduces Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $68.00 at Stifel Nicolaus - Defense World
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - Knox Daily
Stifel raises Ideaya Biosciences stock target, holds buy on drug potential - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $68.00 by Analysts at Stifel Nicolaus - MarketBeat
Bank of New York Mellon Corp Buys 95,129 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Stifel raises Ideaya Biosciences stock target, holds buy on drug potential - Investing.com UK
Bank of New York Mellon Corp Raises Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya Biosciences prepares new PARG inhibitors for cancer - BioWorld Online
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ideaya Biosciences Inc Stock (IDYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Throne Jason | Chief Legal Officer |
Jun 27 '24 |
Option Exercise |
7.77 |
53,484 |
415,587 |
63,484 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Option Exercise |
12.86 |
28,500 |
366,510 |
28,500 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Sale |
36.24 |
28,500 |
1,032,884 |
0 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Option Exercise |
4.31 |
83,856 |
361,419 |
761,743 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Option Exercise |
4.31 |
56,711 |
244,424 |
734,598 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Option Exercise |
4.31 |
34,433 |
148,406 |
712,320 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Sale |
42.90 |
83,856 |
3,597,756 |
677,887 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Sale |
41.61 |
56,711 |
2,359,780 |
677,887 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Sale |
41.81 |
34,433 |
1,439,754 |
677,887 |
| Ruiz Briseno Andres | See Remarks |
Feb 09 '24 |
Sale |
46.02 |
2,000 |
92,045 |
24,531 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):